Physician profile
Sunhee D Woo
NPI 1437293479
$7,441.69
in general payments reported to CMS, 2019-2025
25 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $520 · 2021: $611 · 2022: $602 · 2023: $1,193 · 2024: $1,466 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,207.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,288.81 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,325.67 | 2019-2025 | Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,024.48 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $999.99 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $514.13 | 2019-2025 | Zepbound, Mounjaro |
| Janssen Pharmaceuticals, INC | $266.16 | 2019-2021 | |
| Astellas Pharma US INC | $174.72 | 2024 | Veozah |
| Djo, LLC | $109.53 | 2025 | Cmf |
| Pfizer INC. | $105.00 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $104.93 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $102.89 | 2024-2025 | Rexulti |
| Endo Pharmaceuticals INC. | $72.43 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $60.58 | 2019-2020 | |
| Coloplast Corp | $58.13 | 2025 | |
| Amgen INC. | $31.06 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.78 | 2022 | |
| Dexcom, INC. | $21.80 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $21.69 | 2024 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $21.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.53 | 2019 | |
| Abbott Laboratories | $20.13 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $19.69 | 2022 | |
| Medtronic Vascular, INC. | $19.49 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.32 | 2023 | Xifaxan |
| Insulet Corporation | $14.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunhee Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.